From our meta-analysis, in patients with NSCLC, age group, smoking status, metastasis status/site, EGFR mutation status, and region can predict the potency of PD-1 inhibitors, which individuals with age group <65 years, 65–74 years, active or previous smokers, without brain metastasis, liver metastasis, EGFR wild-type, East Asia and U.S./Canada may benefit from PD-1 inhibitor treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.